1. Introduction
===============

Marine fungi are known as a rich source of structurally diverse and biologically active secondary metabolites, including polyketides, steroids, terpenes and alkaloids. Nevertheless, the potential chemical investigations on marine fungi are limited. In recent decades, bioactive natural products obtained from the marine-derived fungi have attracted the rising attention of organic chemists for discovering new drugs \[[@B1-marinedrugs-12-05563]\].

It was amazing that slight variations of traditional cultivation conditions, such as media compositions, temperature, aeration or the shape of the culturing flask, might lead to the discovery of various types of new natural products by microorganism \[[@B2-marinedrugs-12-05563]\]. As was reported, *Daldinia eschscholzii* was well-known to produce abundant polyketides as a mantis-associated fungus \[[@B3-marinedrugs-12-05563],[@B4-marinedrugs-12-05563]\], which motivated us to investigate the secondary metabolites produced by the marine-associated fungus, *D. eschscholzii*. As part of our ongoing research for structurally unique and bioactive natural products from the *D. eschscholzii*, we obtained a new benzopyran ribonic glycoside (**1**), two new isocoumarin ribonic glycosides (**2** and **3**) and two new alkaloids (**4** and **5**), together with five known derivatives (**6**--**10**) from the scaled-up fermentation of the *D. eschscholzii*. Herein, we describe the isolation, structural elucidation and biological evaluations of these compounds.

2. Results and Discussion
=========================

Chemical Structure Elucidation
------------------------------

The EtOAc extract of the solid medium of *D.* *eschscholzii* was subjected to extensive chromatographic separations over silica gel CC, RP-C~18~ silica gel CC, Sephadex LH-20 and semi-preparative HPLC to yield a new benzopyran ribonic glycoside, daldiniside A (**1**), two new isocoumarin ribonic glycosides, daldinisides B (**2**) and C (**3**), and two new alkaloids (**4** and **5**), along with five known compounds, 2,5-pyrazinedipropanoic acid (**6**) \[[@B5-marinedrugs-12-05563]\], cyclo-(Phe-Tyr) (**7**) \[[@B6-marinedrugs-12-05563]\], de-*O*-methyldiaporthin (**8**) \[[@B7-marinedrugs-12-05563]\], 4,6,8-trihydroxy-3,4-dihydronaphthalen-1(2*H*)-one (**9**) \[[@B8-marinedrugs-12-05563]\] and orcinotriol (**10**) \[[@B9-marinedrugs-12-05563]\], as shown in [Figure 1](#marinedrugs-12-05563-f001){ref-type="fig"}.

![Structures of compounds **1**--**10**.](marinedrugs-12-05563-g001){#marinedrugs-12-05563-f001}

marinedrugs-12-05563-t001_Table 1

###### 

^1^H (400 MHz) and ^13^C (100 MHz) NMR data for compounds **1**--**3**.

  -----------------------------------------------------------------------------------------------------------
  NO.   1 ^a^                         2 ^a^   3 ^b^                                                   
  ----- ----------------------------- ------- ----------------------- ------- ----------------------- -------
  1                                                                   167.8                           167.0

  2     4.21, m                       68.8                                                            

  3     1.68, ddd (4.1,12.0, 14.4)\   38.9                            155.9                           156.7
        2.01, dt (1.9, 14.4)                                                                          

  4     5.04, dd (1.9, 4.1)           60.1    6.31, s                 105.8   6.40, s                 106.7

  4a                                  116.1                           141.2                           140.5

  5                                   158.6   6.58, d (1.8)           104.5   6.70, d (2.1)           104.3

  6     6.72, d (8.2)                 107.9                           166.1                           165.9

  7     7.12, t (8.2)                 130.5   6.62, d (1.8)           103.9   6.89, d (2.1)           103.7

  8     6.49, d (8.2)                 112.0                           164.5                           164.1

  8a                                  157.4                           101.4                           101.5

  9     1.40, d (6.3)                 21.6    2.22, s                 19.4    2.67, dd (4.9, 14.3)\   44.3
                                                                              2.74, dd (7.8, 14.3)    

  10                                                                          4.45, m                 65.4

  11                                                                          1.40, d (6.2)           24.4

  1′    5.70, d (4.5)                 103.4   5.74, d (4.4)           101.8   6.17, d (4.2)           102.1

  2′    4.23, dd (4.5, 6.4)           73.9    4.24, dd (4.4, 6.2)     73.6    4.87, m                 74.1

  3′    4.10, dd (2.6, 6.4)           71.4    4.12, dd (3.0, 6.2)     71.2    4.85, m                 71.3

  4′    4.20, m                       88.5    4.15, m                 88.3    4.88, m                 89.0

  5′    3.64, dd (3.9, 12.1)\         63.5    3.65, dd (3.8, 12.1)\   63.3    4.12, dd (3.8, 12.0)\   63.4
        3.69, dd (3.6, 12.1)                  3.72, dd (3.3, 12.1)            4.17, dd (3.7, 12.0)    
  -----------------------------------------------------------------------------------------------------------

^a^ Measured in CD~3~OD; ^b^ measured in C~5~D~5~N.

Compound **1** was obtained as colorless crystal. Its molecular formula was determined as C~15~H~20~O~7~ by HRESIMS at *m/z* 335.1097 \[M + Na\]^+^ (calcd. for C~15~H~20~O~7~Na, 335.1107), indicating the presence of six degrees of unsaturation. The IR spectrum of **1** showed absorptions of hydroxyl (3423 cm^−1^) and aromatic (1611, 1588 and 1472 cm^−1^) functionalities. The ^1^H-NMR spectrum of **1** ([Table 1](#marinedrugs-12-05563-t001){ref-type="table"}) showed signals at δ~H~ 6.72 (1H, d, *J* = 8.2 Hz), 7.12 (1H, t, *J* = 8.2 Hz) and 6.49 (1H, d, *J* = 8.2 Hz), ascribed to one set of the typical 1,2,3-trisubstituted aromatic ring. Additionally, the ^1^H NMR spectrum of **1** also revealed the signals of one methyl group (δ~H~ = 1.40, d, *J* = 6.3 Hz) and two oxygen-bearing methines at 5.70 (1H, d, *J* = 4.5 Hz) and 5.04 (1H, dd, *J* = 1.9, 4.1 Hz). The ^13^C-NMR spectrum showed one methyl, two methylenes (one oxygenated), nine methines (three aromatic and six oxygenated) and three aromatic quaternary carbons. Furthermore, a series of proton signals at δ~H~ 3.64--5.70 and their corresponding carbons at δ~C~ 63.5, 71.4, 73.9, 88.5 and 103.4 might suggest a pentose moiety.

Analysis of the key ^1^H-^1^H COSY and HMBC correlations ([Figure 2](#marinedrugs-12-05563-f002){ref-type="fig"}) was used to establish the planar structure of **1**. In the HMBC spectrum, a diagnostic long-range correlation from the anomeric proton H-1′ to C-5 (δ~C~ 158.6) suggested that the sugar moiety was linked to the C-5 of aglycone. The remaining one degree of unsaturation, together with the ^1^H-^1^H COSY correlations of H-9/H-2, H-2/H-3 and H-3/H-4 and the HMBC correlations from H-9 to C-2, C-3 and from H-4 to C-2, C-4a, C-5 and C-8a, indicating that a pyranoid ring was linked to C-4a and C-8a, and the methyl and hydroxyl groups were located at C-2 and C-4, respectively. Thus, the planar structure of **1** was established.

![Selected ^1^H-^1^H COSY and HMBC correlations of compounds **1**--**3**.](marinedrugs-12-05563-g002){#marinedrugs-12-05563-f002}

Acid hydrolysis of **1** gave the sugar motif, and then, it was unambiguously established as [d]{.smallcaps}-ribose by chemical transformation and GC analysis. The coupling constant of the anomeric proton at δ~H~ 5.70 (H-1′, d, *J* = 4.5 Hz) in the ^1^H NMR spectrum of **1** indicated the [d]{.smallcaps}-ribose unit to be in the α-configuration \[[@B10-marinedrugs-12-05563]\]. In the NOESY experiment, the correlations of H-2/H-4 or H-9/H-4 were not observed; Thus, it was difficult to determine the configurations at C-2 and C-4. Fortunately, we obtained the crystal of **1**, and a single crystal X-ray diffraction experiment was carried out with Cu Kα radiation ([Figure 3](#marinedrugs-12-05563-f003){ref-type="fig"}), allowing an explicit assignment of the absolute structure as 2*R* and 4*R*. Hence, the absolute configuration of **1** was elucidated and named daldiniside A.

![X-ray structure of compound **1**.](marinedrugs-12-05563-g003){#marinedrugs-12-05563-f003}

Compound **2** was isolated as a yellowish solid with the molecular formula C~15~H~16~O~8~, as deduced by the HRESIMS result (\[M + Na\]^+^ at *m*/*z* 347.0731, calcd. for C~15~H~16~O~8~Na, 347.0743). The presence of hydroxyl, carbonyl and double bond groups were shown by IR absorption bands at 3429, 1689 and 1573 cm^−1^, respectively. The α-[d]{.smallcaps}-ribose group of **2** was confirmed by NMR experiment ([Table 1](#marinedrugs-12-05563-t001){ref-type="table"}) and acid hydrolysis. The attachment of the α-[d]{.smallcaps}-ribose at C-6 was determined on the basis of the HMBC correlation from H-1′ (δ~H~ 5.74) to C-6 (δ~C~ 166.1). Apart from the signals of the sugar moiety, the ^1^H NMR spectrum showed proton signals at δ~H~ 6.58 (1H, d, *J* = 1.8 Hz) and 6.62 (1H, d, *J* = 1.8 Hz), indicating the presence of a 1,2,3,5-tetrasubstituted aromatic ring. This structural assignment was further established by the HMBC correlations from H-5 to C-6, C-7 and C-8a, and from H-7 to C-5, C-6, C-8 and C-8a. The ^13^C NMR spectrum showed one ester carbon signal at C-1 (δ~C~ 167.8), one olefinic carbon signal at C-4 (δ~C~ 105.8) and one methyl carbon signal at C-9 (δ~C~ 19.4). The HMBC correlations ([Figure 2](#marinedrugs-12-05563-f002){ref-type="fig"}) from H-9 to C-3, C-4 and from H-4 to C-3, C-4a, C-5, C-8a and C-9 suggested that there existed an isocoumarin unit, in which the hydroxyl and methyl groups were located at C-8 and C-3, respectively. Thus, the structure of **2** was established, namely, daldiniside B.

Compound **3** was determined to be C~17~H~20~O~9~ by the HRESIMS data, which showed a molecular ion at *m/z* 391.0994 \[M + Na\]^+^ (calcd. for C~17~H~20~O~9~Na, 391.1005). The NMR data of **3**were very similar to those of **2** ([Table 1](#marinedrugs-12-05563-t001){ref-type="table"}), suggesting that they shared the same basic skeleton. Moreover, the signals for a methylene at C-9 (δ~C~ 44.3), an oxygenated methine at C-10 (δ~C~ 65.4) and a methyl at C-11 (δ~C~ 24.4) were observed in the ^13^C NMR of **3**, from which we deduced that a -CH~2~(9)-CH(10)OH-CH~3~(11)- group in **3** replaced a -CH~3~ group in **2**. Hence, the planar structure of **3** was determined ([Figure 2](#marinedrugs-12-05563-f002){ref-type="fig"}). To ascertain the absolute configuration at C-10, an acid hydrolysis experiment was carried out. By the chemical transformation and GC analysis, we established the sugar moiety to be α-[d]{.smallcaps}-ribose. In addition, the CHCl~3~ layer was evaporated to dryness, and the NMR data of the residual compound was identical to de-*O*-methyldiaporthin ($\left\lbrack \text{α} \right\rbrack_{\text{D}}^{20}$: +20.0, *c* 0.09, MeOH). Therefore, the absolute configuration of **3** was established, namely daldiniside C.

Compound **4** was obtained as a colorless crystal. The molecular formula C~11~H~11~NO~3~was determined upon analysis of the HRESIMS peak at *m/z* 228.0628 \[M + Na\]^+^ (calcd. for C~11~H~11~NO~3~Na, 228.0637). UV absorption bands at 210, 243, 257 and 300 nm and IR absorption bands at 3394, 3325 and 1607 cm^−1^ implied the presence of amine, hydroxy and conjugated carbonyl functionalities. In the ^1^H NMR spectrum ([Table 2](#marinedrugs-12-05563-t002){ref-type="table"}), the signals at δ~H~ 12.03 (1H, s), 8.21 (1H, dd, *J* = 2.0, 6.6 Hz), 7.19 (1H, m), 7.23 (1H, m) and 7.49 (1H, dd, *J* = 1.7, 6.8 Hz) indicated the presence of an unsubstituted indole aromatic ring, which was inferred by the ^1^H-^1^H COSY correlations of H-4/H-5, H-5/H-6 and H-6/H-7 ([Figure 4](#marinedrugs-12-05563-f004){ref-type="fig"}). The -CO(8)-CH(9)OH-CH~2~(10)OH- subunit was established by analysis of the ^1^H-^1^H COSY correlation of H-9/H-10 and HMBC correlation from H-10 to C-8 and C-9 and linked to the indole moiety by C-3, determined by the HMBC correlations from H-2 to C-3 and C-8. The configuration at C-9 was unequivocally established to be *R* by the single-crystal X-ray diffraction using Cu Kα radiation ([Figure 5](#marinedrugs-12-05563-f005){ref-type="fig"}). Consequently, the absolute configuration of **4** was established and named 1-(3-indolyl)-2*R*,3-dihydroxypropan-1-one.

marinedrugs-12-05563-t002_Table 2

###### 

^1^H and ^13^C NMR data for compounds **4**--**6**.

  -------------------------------------------------------------------------------------
  NO.   4 ^c^                   5 ^d^   6 ^c^                                   
  ----- ----------------------- ------- --------------- ------- --------------- -------
  1     12.03, s                                                                

  2     8.41, s                 134.8                   152.2                   153.0

  3                             114.1                   157.2   8.44, d (4.1)   143.3

  3a                            125.9                                           

  4     8.21, dd (2.0, 6.6)     121.4                                           

  5     7.19, m                 121.9                   153.9                   153.0

  6     7.23, m                 122.9   8.25, s         141.7   8.44, d (4.1)   143.3

  7     7.49, dd (1.7, 6.8)     112.2   3.10, t (7.2)   29.3    2.96, t (7.3)   29.2

  7a                            136.3                                           

  8                             195.5   2.79, t (7.2)   32.9    2.67, t (7.3)   32.2

  9     4.69, t (4.5)           75.8                    177.1                   173.8

  10    3.63, dd (5.5, 11.1)\   65.3    3.04, t (7.2)   30.7    2.96, t (7.3)   29.2
        3.71, dd (4.5, 11.1)                                                    

  11                                    2.76, t (7.2)   33.9    2.67, t (7.3)   32.2

  12                                                    176.9                   173.8

  13                                    2.88, q (7.5)   28.3                    

  14                                    1.29, t (7.5)   13.1                    
  -------------------------------------------------------------------------------------

^c^ Measured in DMSO-*d*~6~ on a Bruker AM-400 spectrometer; ^d^ measured in CD~3~OD on a Bruker DRX-600 spectrometer.

![Selected ^1^H-^1^H COSY and HMBC correlations of compounds **4** and **5**.](marinedrugs-12-05563-g004){#marinedrugs-12-05563-f004}

![X-ray structure of compound **4**.](marinedrugs-12-05563-g005){#marinedrugs-12-05563-f005}

Compound **5** was isolated as a yellow oil with the molecular formula C~10~H~12~N~2~O~4~ as determined by the HRESIMS peak at *m/z* 275.0998 \[M + Na\]^+^ (calcd. for C~12~H~16~N~2~O~4~Na, 275.1008). In the 2D NMR spectra of **5** ([Figure 4](#marinedrugs-12-05563-f004){ref-type="fig"}), the ^1^H-^1^H COSY correlations of H-7/H-8 and H-10/H-11 and the HMBC correlations from H-8 to C-2 and C-9, from H-11 to C-5 and C-12 and from H-6 to C-2 and C-5 indicated the existence of the 2,5-pyrazinedipropanoic acid group. An additional ethyl moiety was located at C-3 by the ^1^H-^1^H COSY correlation of H-13/H-14 and a long-rang HMBC correlation from H-14 to C-3. Thus, the structure of **5** was established and named 3-ethyl-2,5-pyrazinedipropanoic acid, whose signals were similar to **6** ([Table 2](#marinedrugs-12-05563-t002){ref-type="table"}), confirmed by a single-crystal X-ray diffraction using Mo Kα radiation ([Figure 6](#marinedrugs-12-05563-f006){ref-type="fig"}).

![X-ray structure of compound **6**.](marinedrugs-12-05563-g006){#marinedrugs-12-05563-f006}

3. Experimental Section
=======================

3.1. General Experimental Procedures
------------------------------------

UV spectra were measured on a Varian Cary 50 spectrophotometer or a Shimadzu UV-2401A spectrophotometer. Optical rotations were recorded on a Perkin-Elmer PE-341LC polarimeter. IR spectra were determined on a Bruker Vertex 70 FT-IR spectrophotometer. The ^1^H, ^13^C, and 2D NMR spectroscopic data were recorded on Bruker AM-400 and DRX-600 spectrometers using TMS as the internal standard. HRESIMS data were acquired using an APIQSTAR Pulsar spectrometer. X-ray data were collected using a Bruker APEX DUO diffractometer. Column chromatography was performed on silica gel (100--200 mesh and 200--300 mesh, Qingdao Marine Chemical Inc., Qingdao, China), RP-C~18~ silica gel (50 μm, YMC, Kyoto, Japan) and Sephadex LH-20 (Pharmacia Biotech AB, Uppsala, Sweden). Semi-preparative HPLC was conducted on an Agilent 1100 liquid chromatography with a YMC-Pack ODS-A (10 × 250 mm, 5μm, YMC Co., Ltd., Kyoto, Japan) column. GC analysis was performed with an Agilent Technologies 6890N gas chromatography system. Solvents were distilled prior to use, and spectroscopic grade solvents were used. TLC was performed with silica gel 60 F254 (Yantai Chemical Industry Research Institute, Yantai, China) and RP-C~18~ F254 plates (Merck, Darmstadt, Germany). Peptone (produced by protamine with enzymatic hydrolysis and drying into a pale yellow powder) was purchased from Beijing Shuangxuan Microbial Medium Plant (Product ID: 02-31A, Specification: BR).

3.2. Fungal Material and Fermentation
-------------------------------------

The strain of fungus *D. eschscholzii* was isolated from the branches of *Scaevola sericea* Vahl, collected from the mangrove forest nature reserve in Haikou, Hainan province, China. The fungus was identified by sequence analysis of the ITS region of its rDNA, as described previously \[[@B11-marinedrugs-12-05563]\], and the sequence data have been deposited in NCBI with Accession Number FJ624265. A voucher specimen (MCCC 3J00088) was deposited in a public collection, the Marine Culture Collection of China, MCCC. All of the information and strains collected can be shared at the website <http://www.mccc.org.cn/> and the collection center.

The strain *D. eschscholzii* was cultivated on a potato dextrose agar (PDA) plate at 25 °C for 15 days. The agar was cut into pieces (0.5 × 0.5 cm^2^) and inoculated into 100 × 500 mL Erlenmeyer (composition: normal rice (100 g), peptone (0.5 g), in distilled water (100 mL)) at 28 °C for 21 days under static conditions.

3.3. Extraction and Isolation
-----------------------------

The fermented rice substrate was extracted four times with EtOAc (4 × 25 L) at room temperature. After concentration*in vacuo*, the total extract (145.0 g) was suspended in water and then extracted exhaustively with petroleum ether and EtOAc, respectively. The EtOAc organic phase was evaporated under reduced pressure to afford a crude extract (77.0 g), which was subjected to silica gel column chromatography (CC) with a CH~2~Cl~2~/CH~3~OH gradient system (1:0, 50:1, 25:1, 10:1, 6:1, 3:1 and 1:1, v/v, each 8 L) to obtain six main fractions (A−F).

Fraction C (CH~2~Cl~2~/CH~3~OH, 10:1; 8.6 g) was subjected to RP-C~18~ silica gel CC (CH~3~OH/H~2~O, 20:80 to 100:0, 12 L) to get five subfractions (C1--C5). Subfraction C2 (CH~3~OH/H~2~O, 40:60; 2.8 g) was subjected to Sephadex LH-20 (CH~3~OH, 1.2 L), then separated by silica gel CC eluted with CH~2~Cl~2~--CH~3~OH (50:1, v/v, 1.9 L) and by semi-preparative HPLC using CH~3~OH--H~2~O (2.5 mL/min, CH~3~OH:H~2~O = 50:50, v/v) and CH~3~CN--H~2~O (2.5 mL/min, CH~3~CN:H~2~O = 14:86, v/v) to yield **8** (7.4 mg, *t*~R~ = 22.0 min) and **9** (2.6 mg, *t*~R~ = 37.0 min), respectively. Subfraction C3 (CH~3~OH/H~2~O, 60:40; 1.2 g) was fractionated by Sephadex LH-20 CC with CH~2~Cl~2~/CH~3~OH (1:1, v/v, 650 mL), silica gel CC (CH~2~Cl~2~--CH~3~OH, 100:1, 1.1 L) and further purified by semi-preparative HPLC using CH~3~OH--H~2~O (2.5 mL/min, CH~3~OH:H~2~O = 60:40, v/v) to obtain **5** (12.3 mg, *t*~R~ = 11.7 min).

Fraction D (CH~2~Cl~2~/CH~3~OH, 6:1; 9.5 g) was subjected to RP-C~18~ silica gel CC eluted with CH~3~OH--H~2~O (20:80 to 100:0, 16 L) to afford five subfractions (D1--D5). Subfraction D1 (CH~3~OH/H~2~O, 20:80; 2.1 g) was crystallized in CH~3~OH to yield **6** (30.5 mg) and then chromatographed over Sephadex LH-20 with CH~2~Cl~2~/CH~3~OH (1:1, v/v, 1.3 L), followed by RP-C~18~ silica gel CC eluted with CH~3~OH--H~2~O (10:90 to 20:80, v/v, 4 L) to yield four fractions (D1.1--D1.4). Fraction D1.2 (CH~3~OH/H~2~O, 10:90; 505.0 mg) was subjected to silica gel CC (CH~2~Cl~2~--CH~3~OH, 75:1, 750 mL) and purified by semi-preparative HPLC (2.5 mL/min, CH~3~CN/H~2~O, 13:87) to yield **10** (14.4 mg, *t*~R~ = 14.7 min). Fraction D1.3 (CH~3~OH/H~2~O, 15:85; 75.0 mg) was subjected to silica gel CC (CH~2~Cl~2~--CH~3~OH, 50:1, 450 mL) and further purified by semi-preparative HPLC (2.5 mL/min, CH~3~OH/H~2~O, 20:80) to get **4** (11.4 mg, *t*~R~ = 40.0 min). Subfraction D2 (CH~3~OH/H~2~O, 40:60; 2.2 g) was fractionated by Sephadex LH-20 CC with CH~3~OH (1.2 L), followed by silica gel CC eluted with CH~2~Cl~2~--CH~3~OH (50:0 to 20:1, v/v, 1.8 L) to obtain three fractions (D2.1--D2.3). Fraction D2.3 (CH~2~Cl~2~/CH~3~OH, 20:1; 300.0 mg) was purified by semi-preparative HPLC (2.5 mL/min, CH~3~OH/H~2~O, 30:70) to obtain **3** (250.0 mg, *t*~R~ = 37.5 min). Fraction D2.2 (CH~2~Cl~2~/CH~3~OH, 30:1; 1.2 g) was successively purified by semi-preparative HPLC using CH~3~CN−H~2~O (2.5 mL/min, CH~3~CN:H~2~O = 30:70, v/v) to yield **2** (23.0 mg, *t*~R~ = 11.0 min) and CH~3~CN--H~2~O (2.5 mL/min, CH~3~CN:H~2~O = 17:83, v/v) to yield **1** (6.5 mg, *t*~R~ = 36.2 min) and **7** (6.0 mg, *t*~R~ = 39.0 min), respectively.

Daldiniside A (**1**): Colorless crystal; $\left\lbrack \text{α} \right\rbrack_{\text{D}}^{20}$: +106.3 (*c* = 0.16 mg/mL, MeOH); UV (MeOH) λ~max~ (log ε): 206 (4.41), 225 (3.78) and 282 (3.18) nm; IR (KBr) ν~max~: 3423, 2926, 1611, 1588, 1472, 1263, 1244, 1126, 1088, 1044, 1026 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-12-05563-t001){ref-type="table"}; HRESIMS *m/z* 335.1097 \[M + Na\]^+^ (calcd. for C~15~H~20~O~7~Na, 335.1107).

Daldiniside B (**2**): Yellowish powder; $\left\lbrack \text{α} \right\rbrack_{\text{D}}^{20}$: +14.1 (*c* = 0.67 mg/mL, MeOH); UV (MeOH) λ~max~ (log ε): 236 (4.56), 243 (4.57) and 329 (3.69) nm; IR (KBr) ν~max~: 3429, 2926, 1689, 1644, 1624, 1573, 1506, 1385, 1354, 1235, 1172, 1074, 1043, 694 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-12-05563-t001){ref-type="table"}; HRESIMS *m/z* 347.0731 \[M + Na\]^+^ (calcd. for C~15~H~16~O~8~Na, 347.0743).

Daldiniside C (**3**): Yellowish powder; $\left\lbrack \text{α} \right\rbrack_{\text{D}}^{20}$: +45.0 (*c* = 0.13 mg/mL, MeOH); UV (MeOH) λ~max~ (log ε): 203 (3.62), 244 (3.92) and 334 (3.06) nm; IR (KBr) ν~max~: 3427, 2924, 1686, 1626, 1505, 1384, 1240, 1171, 1127, 1083, 1045, 695 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-12-05563-t001){ref-type="table"}; HRESIMS *m/z* 391.0994 \[M + Na\]^+^ (calcd. for C~17~H~20~O~9~Na, 391.1005).

1-(3-indolyl)-2*R*,3-dihydroxypropan-1-one (**4**): Colorless crystal; $\left\lbrack \text{α} \right\rbrack_{\text{D}}^{20}$: +20.0 (*c* = 0.70 mg/mL, MeOH); UV (MeOH) λ~max~ (log ε): 210 (4.19), 243 (3.82), 257 (3.70) and 300 (3.82) nm; IR (KBr) ν~max~: 3394, 3325, 1607, 1520, 1442, 1156, 1090, 986, 742, 705 cm^−1^; ^1^H and ^13^C NMR data, see [Table 2](#marinedrugs-12-05563-t002){ref-type="table"}; HRESIMS *m/z* 228.0628 \[M + Na\]^+^ (calcd. for C~11~H~11~NO~3~Na, 228.0637).

3-ethyl-2,5-pyrazinedipropanoic acid (**5**): Yellow oil; UV (MeOH) λ~max~ (log ε): 210 (3.94), 243 (3.18) and 279 (3.86) nm; IR (KBr) ν~max~: 2975, 2935, 1714, 1452, 1392, 1251, 1177, 1122 cm^−1^; ^1^H and ^13^C NMR data, see [Table 2](#marinedrugs-12-05563-t002){ref-type="table"}; HRESIMS *m/z* 275.0998 \[M + Na\]^+^ (calcd. for C~12~H~16~N~2~O~4~Na, 275.1008) and *m/z* 253.1178 \[M + H\]^+^ (calcd. for C~12~H~17~N~2~O~4~, 253.1188).

3.4. X-ray Crystallographic Analysis
------------------------------------

Crystal data for **1**: C~15~H~20~O~7~, *M* = 312.31, orthorhombic, *a* = 5.3212(2) Å, *b* = 10.3774(4) Å, *c* = 26.8183(9) Å, *α* = 90.00°, *β* = 90.00°, *γ* = 90.00°, *V* = 1480.91(9) Å^3^, *T* = 100(2) K, space group *P*212121, *Z* = 4, *μ*(Cu Kα) = 0.943 mm^−1^, 10,224 reflections measured, 2578 independent reflections (*R~int~* = 0.1191). The final *R~1~* values were 0.1218 (*I* \> 2*σ*(*I*)). The final *wR*(*F*^2^) values were 0.3053 (*I* \> 2*σ*(*I*)). The final *R~1~* values were 0.1580 (all data). The final *wR*(*F*^2^) values were 0.3760 (all data). The goodness of fit on *F*^2^ was 1.445. Flack parameter = 0.0 (7).

Crystal data for **4**: C~11~H~11~NO~3~, *M* = 205.21, monoclinic, *a* = 4.7449(5) Å, *b* = 5.4635(5) Å, *c* = 17.8653(16) Å, *α* = 90.00°, *β* = 95.820(5)°, *γ* = 90.00°, *V* = 460.75(8) Å^3^, *T* = 100(2) K, space group *P*21, *Z* = 2, *μ*(Cu Kα) = 0.903 mm^−1^, 3,878 reflections measured, 1,498 independent reflections (*R*~int~ = 0.0490). The final *R~1~* values were 0.0523 (*I* \> 2*σ*(*I*)). The final *wR*(*F^2^*) values were 0.1467 (I \> 2σ(I)). The final *R~1~* values were 0.0527 (all data). The final *wR*(*F^2^*) values were 0.1470 (all data). The goodness of fit on *F^2^* was 1.109. Flack parameter = −0.4(4). The Hooft parameter is 0.02(13) for 567 Bijvoet pairs.

Crystal data for **6**: C~10~H~12~N~2~O~4~, *M* = 224.22, monoclinic, *a* = 5.6215(9) Å, *b* = 13.275(2) Å, *c* = 7.0331(11) Å, *α* = 90.00°, *β* = 105.791(2)°, *γ* = 90.00°, *V* = 505.04(14) Å^3^, *T* = 100(2) K, space group *P*21*/n*, *Z* = 2, *μ*(Mo Kα) = 0.116 mm^−1^, 5,086 reflections measured, 1415 independent reflections (*R~int~* = 0.0238). The final *R~1~* values were 0.0368 (*I* \> 2*σ*(*I*)). The final *wR*(*F*^2^) values were 0.0918 (*I* \> 2*σ*(*I*)). The final *R~1~* values were 0.0380 (all data). The final *wR*(*F*^2^) values were 0.0926 (all data). The goodness of fit on *F*^2^ was 1.088.

The crystallographic data for **1** (deposition No. CCDC 989294), **4** (deposition No. CCDC 981181), and **6** (deposition No. CCDC 981180) have been deposited in the Cambridge Crystallographic Data Centre. Copies of the data can be obtained free of charge from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB21EZ, UK (fax: +44-1223-336-033; or E-Mail: [deposit\@ccdc.cam.ac.uk](deposit@ccdc.cam.ac.uk)).

3.5. Acid hydrolysis and GC Analysis of **1**−**3** and Determination of the Absolute Configuration of the Sugar Moiety
-----------------------------------------------------------------------------------------------------------------------

Compound **1** (1.2 mg) was hydrolyzed with 2 M aqueous CF~3~COOH (2.0 mL) at 90 °C for 6 h. The reaction mixture was evaporated to dryness; Then, the residue and [l]{.smallcaps}-cysteine methyl ester hydrochloride (2.5 mg) were dissolved in dry pyridine (1.0 mL) and kept at 65 °C for 2 h. The reaction mixture was dried, and then, trimethylsilylimidazole (0.2 mL) was added to the residue, followed by stirring at 65 °C for 1 h \[[@B12-marinedrugs-12-05563]\]. In the end, the resultant solution was extracted with water and *n*-hexane, and then, the organic phase was submitted to GC analysis by using an HP-5MS capillary column (30 m × 0.25 mm × 0.25 μm, Agilent, Shanghai, China); column temperature, 230 °C; injection temperature, 250 °C; detector FID, detector temperature, 250 °C. A peak at the retention time of 12.61 min for compound **1** was observed. When the corresponding ribose was prepared by the same reaction, the retention times of presilylated [d]{.smallcaps}-ribose and [l]{.smallcaps}-ribose were 12.66 and 14.09 min, respectively. Hence, the sugar in compound **1**was determined to be [d]{.smallcaps}-ribose.

Compounds **2** (1.5 mg) and **3** (9.8 mg) were subjected to a similar treatment as compound **1**, and the retention times of ribose were 12.63 and 12.66 min, respectively. Therefore, the sugar in compounds **2** and **3** were determined to be [d]{.smallcaps}-ribose. In addition, the reaction mixture of compound **3** was diluted with H~2~O (1.5 mL) and extracted with CHCl~3~. The CHCl~3~ layer was dried to yield the aglycone, whose NMR and optical rotation data were identical to de-*O*-methyldiaporthin ($\left\lbrack \text{α} \right\rbrack_{\text{D}}^{20}$: +20.0, *c* 0.09, MeOH) \[[@B7-marinedrugs-12-05563]\].

3.6. Biological Activities
--------------------------

The cytotoxicity of **1**--**10** against HL-60, SMMC-7721, A-549, MCF-7 and SW-480 was studied using the MTT method \[[@B13-marinedrugs-12-05563]\], and the results showed no obvious inhibitory activity toward the above cancer cells with IC~50~ \> 40 μg/mL. In addition, compounds **1**--**5** were tested for antifungal activities against *Candida albicans* (ATCC32354 and ATCC10231) at a concentration of 128 μg/mL and anti-HIV activity according to the described method \[[@B14-marinedrugs-12-05563],[@B15-marinedrugs-12-05563]\]; Unfortunately, none of the compounds exhibited significant activities. Otherwise, the *in vitro* assay for glucose consumption of compounds **1**--**3** was done in the anti-diabetic model with DMEM-induced 3T3 fibroblasts \[[@B16-marinedrugs-12-05563]\], whereas none showed obvious activity at the concentration of 20 μg/mL.

4. Conclusions
==============

A new benzopyran glycoside, daldiniside A (**1**), two new isocoumarin glycosides, daldinisides B (**2**) and C (**3**), and two new alkaloids, 1-(3-indolyl)-2*R*,3-dihydroxypropan-1-one (**4**) and 3-ethyl-2,5-pyrazinedipropanoic acid (**5**), together with five known compounds, 2,5-pyrazinedipropanoic acid (**6**), cyclo-(Phe-Tyr) (**7**), de-*O*-methyldiaporthin (**8**), 4,6,8-trihydroxy-3,4-dihydronaphthalen-1(2*H*)-one (**9**) and orcinotriol (**10**), were discovered from the marine-associated fungus, *D. eschscholzii*. Natural products embodying the α-[d]{.smallcaps}-ribose moiety were quite scarce to be reported. To the best of our knowledge, compounds **2** and **3** were hitherto the first example of isocoumarins containing the α-[d]{.smallcaps}-ribose moiety in natural products. Interestingly, the nonenzymatic cyclic dimerization of 5-aminolevulinic acid (5-ALA) might be the key reaction to form a pyrazine nucleus, and a series of derivatives might lead to the formation of **5** and **6** \[[@B17-marinedrugs-12-05563]\].
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